ACE 2 with covid 19

University of British Colombia -Canada ACE2 — a protein on the surface of the cell membrane — is now at centre-stage in this outbreak as the key receptor for the spike glycoprotein of SARS-CoV-2. hrsACE2, a genetically modified protein already being tested to prevent lung disease, reduces the viral growth of SARS-CoV-2 by a factor of 1,000 to 5,000 in human cell cultures. Researchers believe the enzyme copy lures the virus to attach itself to the copy, rather than human lung cells. The findings suggest hrsACE2 could significantly block the early stages of SARS-CoV-2 infections and prevent COVID-19 from becoming severe The new study provides very much needed direct evidence that a drug — called APN01 (human recombinant soluble angiotensin-converting enzyme 2 – hrsACE2) — soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19,” says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michael’s Hospital and professor at the University of Toronto who is a collaborator on the study.

1 Like

Nice to know.